ARS Pharmaceuticals Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über ARS Pharmaceuticals Inc Unternehmen

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

ARS Pharmaceuticals Inc Informationen



BörsenkürzelSPRY

Name des UnternehmensARS Pharmaceuticals Inc

IPO-datumDec 04, 2020

CEOMr. Richard E. Lowenthal

Anzahl der mitarbeiter155

WertpapierartOrdinary Share

GeschäftsjahresendeDec 04

Addresse11682 El Camino Real, Suite 120

StadtSAN DIEGO

BörseNASDAQ Global Market Consolidated

LandUnited States of America

Postleitzahl92130

Telefon18587719307

Websitehttps://ars-pharma.com/

BörsenkürzelSPRY

IPO-datumDec 04, 2020

CEOMr. Richard E. Lowenthal

Führungskräfte von ARS Pharmaceuticals Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Richard E. Lowenthal

President, Chief Executive Officer, Director

6.83M

-14.34%

Dr. Sarina Tanimoto, M.D.

Chief Medical Officer

4.57M

-10.85%

Mr. Justin Chakma

Chief Business Officer

136.38K

--

Mr. Alexander A. Fitzpatrick, Esq., J.D.

Secretary and Chief Legal Officer

86.26K

-3.33%

Mr. Michael Kelly

Independent Director

83.22K

--

Mr. Brian T. Dorsey

Chief Operating Officer

7.65K

--

Dr. Laura K. Shawver, Ph.D.

Director

--

Dr. Rajeev Dadoo, Ph.D.

Independent Director

--

Ms. Kathleen D. (Kathy) Scott

Chief Financial Officer

--

Dr. Pratik Shah, Ph.D.

Chairman of the Board

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Richard E. Lowenthal

President, Chief Executive Officer, Director

6.83M

-14.34%

Dr. Sarina Tanimoto, M.D.

Chief Medical Officer

4.57M

-10.85%

Mr. Justin Chakma

Chief Business Officer

136.38K

--

Mr. Alexander A. Fitzpatrick, Esq., J.D.

Secretary and Chief Legal Officer

86.26K

-3.33%

Mr. Michael Kelly

Independent Director

83.22K

--

Mr. Brian T. Dorsey

Chief Operating Officer

7.65K

--

Umsatzaufteilung

Keine Daten

Keine Daten

Nach Geschäftsbereich

Nach Region

Keine Daten

Aktionärsstatistik

Aktualisiert: Wed, Sep 3

Aktionäre

Aktionärstypen

Aktionäre

Anteil

RA Capital Management, LP

11.07%

OrbiMed Advisors, LLC

8.39%

Deerfield Management Company, L.P.

7.70%

Lowenthal (Richard E)

6.91%

Pratik Shah Living Trust

4.88%

Andere

61.05%

Aktionäre

Anteil

RA Capital Management, LP

11.07%

OrbiMed Advisors, LLC

8.39%

Deerfield Management Company, L.P.

7.70%

Lowenthal (Richard E)

6.91%

Pratik Shah Living Trust

4.88%

Andere

61.05%

Aktionärstypen

Aktionäre

Anteil

Hedge Fund

21.29%

Investment Advisor

19.12%

Investment Advisor/Hedge Fund

18.57%

Venture Capital

15.15%

Individual Investor

12.08%

Private Equity

8.39%

Corporation

4.88%

Research Firm

2.70%

Sovereign Wealth Fund

0.44%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

372

85.58M

86.60%

-4.54M

2025Q2

367

96.00M

97.76%

-11.66M

2025Q1

380

100.63M

102.48%

-12.75M

2024Q4

345

96.62M

99.42%

-14.07M

2024Q3

320

88.19M

90.90%

-18.52M

2024Q2

291

87.17M

89.94%

-20.35M

2024Q1

289

89.45M

92.60%

-16.44M

2023Q4

280

92.18M

96.08%

-6.49M

2023Q3

283

95.82M

104.35%

+1.21M

2023Q2

278

88.26M

96.94%

-730.20K

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

RA Capital Management, LP

10.94M

11.07%

+80.00K

+0.74%

Sep 29, 2025

OrbiMed Advisors, LLC

8.29M

8.39%

--

Jun 30, 2025

Deerfield Management Company, L.P.

7.61M

7.7%

-2.11M

-21.74%

Jul 30, 2025

Lowenthal (Richard E)

6.83M

6.91%

-1.14M

-14.34%

Mar 31, 2025

Pratik Shah Living Trust

4.82M

4.88%

--

Mar 31, 2025

Tanimoto (Sarina)

4.57M

4.63%

-556.66K

-10.85%

Mar 31, 2025

SR One Capital Management, LP

4.01M

4.06%

--

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

3.93M

3.98%

+47.01K

+1.21%

Jun 30, 2025

AllianceBernstein L.P.

3.83M

3.87%

-97.01K

-2.47%

Jun 30, 2025

The Vanguard Group, Inc.

3.25M

3.29%

-228.66K

-6.57%

Jun 30, 2025

Verbundene ETFs



Aktualisiert: Thu, Oct 2

Name

Anteil

Invesco Dorsey Wright Healthcare Momentum ETF

0.86%

ALPS Medical Breakthroughs ETF

0.67%

First Trust Small Cap Growth AlphaDEX Fund

0.39%

SPDR S&P Biotech ETF

0.23%

First Trust Small Cap Core Alphadex Fund

0.19%

Direxion Daily S&P Biotech Bull 3X Shares

0.14%

Invesco Nasdaq Biotechnology ETF

0.12%

ProShares Ultra Nasdaq Biotechnology

0.12%

Principal U.S. Small-Cap ETF

0.09%

First Trust Multicap Growth Alphadex Fund

0.08%

Invesco Dorsey Wright Healthcare Momentum ETF

Anteil0.86%

ALPS Medical Breakthroughs ETF

Anteil0.67%

First Trust Small Cap Growth AlphaDEX Fund

Anteil0.39%

SPDR S&P Biotech ETF

Anteil0.23%

First Trust Small Cap Core Alphadex Fund

Anteil0.19%

Direxion Daily S&P Biotech Bull 3X Shares

Anteil0.14%

Invesco Nasdaq Biotechnology ETF

Anteil0.12%

ProShares Ultra Nasdaq Biotechnology

Anteil0.12%

Principal U.S. Small-Cap ETF

Anteil0.09%

First Trust Multicap Growth Alphadex Fund

Anteil0.08%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten